Neuphoria Therapeutics Inc.
NEUP
$4.12
-$0.25-5.72%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | 16.89% | 34.84% | -14.64% | -- |
| Gross Profit | -- | -17.10% | 1,216.73% | 47.21% | -- |
| SG&A Expenses | 12.01% | -13.07% | 17.67% | 4.42% | -29.95% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 58.44% | 6.30% | 26.49% | -8.93% | -34.75% |
| Operating Income | -58.44% | -6.54% | 600.13% | 23.80% | 34.75% |
| Income Before Tax | -960.97% | -236.27% | 504.84% | 57.91% | 82.99% |
| Income Tax Expenses | 73.68% | -681.82% | -595.12% | 133.33% | -279.89% |
| Earnings from Continuing Operations | -1,130.93% | -230.62% | 505.39% | 57.33% | 85.29% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1,130.93% | -230.62% | 505.39% | 57.33% | 85.29% |
| EBIT | -58.44% | -6.54% | 600.13% | 23.80% | 34.75% |
| EBITDA | -61.28% | -6.75% | 644.74% | 24.72% | 35.83% |
| EPS Basic | -611.39% | -39.24% | 331.35% | 76.78% | -16,656.76% |
| Normalized Basic EPS | -513.23% | 19.76% | 331.03% | 77.09% | -19,513.04% |
| EPS Diluted | -611.39% | -39.22% | 331.30% | 76.78% | -16,656.76% |
| Normalized Diluted EPS | -513.23% | 19.76% | 331.03% | 77.09% | -19,513.04% |
| Average Basic Shares Outstanding | 73.04% | 137.44% | 75.24% | 83.74% | -99.91% |
| Average Diluted Shares Outstanding | 73.04% | 137.44% | 75.24% | 83.74% | -99.91% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |